Prevention & Prognosis

1. The Prevention Imperative

The diabetic-foot literature is unanimous: prevention is the only intervention that meaningfully changes the population-level burden of diabetic foot disease, including Charcot. Once CN has occurred, the foot is permanently altered — even after optimal Stage III management, ulceration risk remains elevated, contralateral CN risk is ∼30% over the patient’s remaining lifetime, and overall mortality is high.

The major modifiable points along the causal pathway:

1. Prevent diabetes — lifestyle, public health.
2. If diabetes, prevent neuropathy — intensive glycaemic control reduces neuropathy incidence by ~60% (DCCT/EDIC).
3. If neuropathy, prevent the precipitating event — appropriate footwear, foot inspection, careful foot hygiene.
4. If precipitating event, recognise CN at Stage 0 — prompt MRI, immediate offloading.
5. If active CN, optimal conservative management — total contact casting; Part VI.
6. If consolidated CN, prevent ulceration — custom footwear, surveillance.
7. If ulceration, heal it before complication — offloading, debridement, infection control.
8. If amputation, optimal rehabilitation — prevent contralateral disease.

Each rung of this ladder offers measurable risk reduction. The patient who ascends one rung at a time generally survives with limbs and function; the patient who falls multiple rungs in succession ends up in the late chapters of this course.

2. Glycaemic Control — The Foundation

The Diabetes Control and Complications Trial (DCCT, NEJM 1993) established the principle: in T1DM, intensive insulin therapy reducing HbA1c to ~7% (vs ~9% conventional) reduced the development of confirmed clinical neuropathy by 60% over a mean 6.5-year follow-up. The EDIC follow-up showed that the benefit persisted for decades after intensification (the “metabolic memory” phenomenon). The UKPDS (Lancet 1998) demonstrated parallel benefit in T2DM.

For neuropathy and Charcot prevention, the evidence-based glycaemic targets are:

• HbA1c <7% in most non-frail adults.
• HbA1c <7.5% in older adults, longer-duration disease, or limited life expectancy.
• HbA1c <8% in frail elderly or extensive comorbidity.
• Avoid hypoglycaemia — especially in patients with autonomic neuropathy who lose hypoglycaemia awareness.

Once symptomatic neuropathy is established, intensive glycaemic control has limited reversal effect (DCCT showed primary prevention >> secondary prevention). The implication: glycaemic control matters early. The newly diagnosed T2 diabetic with HbA1c 9% has a decade-long window in which control reduces foot disease; the same patient at HbA1c 9% twenty years later has lost much of that window.

Adjacent metabolic risk factors: blood pressure <130/80 (reduces microvascular complications), LDL <70 mg/dL for diabetics with established cardiovascular disease, smoking cessation (strongest single modifiable PAD risk factor). The ABCDE mnemonic (A1c, Blood pressure, Cholesterol, Diet/Drugs, Exercise) captures the bundle.

3. The Annual Diabetic Foot Exam

Every diabetic patient should have an annual comprehensive foot exam (ADA Standards of Care; IWGDF). The exam takes ~5 minutes and risk-stratifies the patient for the screening intensity of the next year.

1. Inspection — skin (fissures, callus, dryness), nails (onychomycosis, ingrown), interdigital spaces, hidden ulcers, deformity (claw toe, hammer toe, hallux rigidus, Charcot rocker-bottom).
2. Sensation — Semmes-Weinstein 5.07 monofilament at 4–10 plantar sites; 128 Hz tuning fork at hallux IP; Ipswich Touch Test as alternative.
3. Pulses — dorsalis pedis and posterior tibial; ABI/TBI if indicated; capillary refill, hair, dry skin signs.
4. Reflexes — Achilles reflex (often absent in DPN).
5. Mobility — passive range of motion of ankle, subtalar, MTP-1; Silfverskiöld test for equinus.
6. Footwear — check the shoes worn that day for fit, wear pattern, foreign objects, callus correlation.
7. Risk classification — assign to IWGDF category 0–3 (Part III) and document in the chart.

In high-risk patients (categories 2–3), the exam is repeated every 3–6 months by the primary clinician and at every visit by the specialist (podiatry, foot & ankle ortho). Skin-temperature monitoring (home infrared thermometer or smart mat) is appropriate for category 3 patients.

4. Patient Education & Self-Care

The neuropathic patient cannot rely on pain to warn them. They must substitute structured visual and tactile inspection for the missing nociception. The IWGDF and ADA endorse the following daily checklist for high-risk patients:

• Inspect both feet daily — top, bottom (with mirror or partner), between toes; look for redness, swelling, blisters, cracks, ulcers, ingrown nails.
• Wash and dry — warm (not hot — check water with hand or thermometer) water; pat dry, especially between toes.
• Moisturise — emollient on dorsum and plantar surface; avoid between toes (maceration).
• Trim nails carefully — straight across; do not cut into corners; consider professional trimming for high-risk patients.
• Never barefoot — even at home; risk of foreign body, hot floor, sharp object.
• Inspect shoes — before wearing, run hand inside; check for foreign objects, worn lining, displaced insole.
• Wear prescribed footwear — for all weight-bearing.
• Report any change immediately — warmth, swelling, ulcer, pain.
• Smoking cessation.
• Glycaemic adherence.

Structured patient education programmes — usually delivered by specialised diabetic foot nurses or podiatrists — have demonstrably reduced ulcer incidence and major amputation in cluster randomised trials (Lincoln et al., Diabetologia 2008; Vatankhah et al., J Diabetes Complications 2009). The educational dose-response: more contact time, more effect.

For the Charcot patient specifically: recognise the warm-foot warning sign. Any unilateral warm, swollen foot — even without pain — warrants urgent assessment and offloading. Recurrence in the same foot, or new contralateral involvement, can be intercepted at Stage 0 if the patient is educated to act early.

5. Footwear & Pressure Offloading

Therapeutic footwear is the most effective lifelong preventive intervention for the Charcot or post-Charcot foot:

Bus, Reiber and others have established that custom-made footwear with proven peak plantar pressure reduction >25% reduces ulcer recurrence by ~50% (RCT data, Bus et al., Diabetes Care 2013). The corollary: footwear that does not measurably reduce pressure does not measurably reduce ulceration. Pressure mapping should be used to verify the prescription.

Wear-time is the limiting factor. Patients prescribed therapeutic footwear wear them only ~30% of the day on average; high-recurrence patients fall below that. The most predictive question in clinic:“Can I see what shoes you walked in today?”

6. The Multidisciplinary Diabetic Foot Clinic

Strong evidence supports the integrated multidisciplinary diabetic foot clinic as the highest-impact organisational intervention. Models vary but generally include:

• Diabetologist / endocrinologist — metabolic control, comorbidity management.
• Podiatrist — foot examination, callus and nail care, offloading.
• Foot & ankle orthopaedic surgeon — reconstruction, amputation.
• Vascular surgeon — revascularisation.
• Infectious-disease physician — osteomyelitis, sepsis.
• Wound-care nurse — dressing, NPWT, education.
• Pedorthist / orthotist — custom footwear, CROW, AFO.
• Diabetes educator — patient education.
• Plastic / reconstructive surgery — soft-tissue coverage when needed.

Outcome data are striking: implementation of an integrated MDT consistently reduces major amputation rates by 30–75% (Krishnan et al., Diabetes Care 2008 Manchester study; Driver et al.; van Houtum et al.; van Acker). The same data show falls in admission length and overall cost.

The “toe-and-flow” model of Armstrong & Mills (J Vasc Surg 2014) frames the MDT as a partnership between the “toe doctor” (podiatrist or foot & ankle ortho) and the “flow doctor” (vascular surgeon) operating from a shared clinic and shared admission pathway. This is the most effective organisational reform documented in the diabetic-foot literature.

7. Prosthetics & The Amputee

When prevention has failed and amputation occurs, the goal becomes functional rehabilitation: prevention of contralateral disease, restoration of ambulation, and preservation of independence.

• Toe / ray amputation — functional with custom shoe and toe-filler insole.
• Transmetatarsal amputation (TMA) — with TAL to prevent equinus; custom shoe with rigid-rocker carbon-fibre footplate.
• Lisfranc / Chopart / Syme — mostly historical; unstable, often revised to BKA.
• Below-knee amputation (BKA) — the workhorse major amputation; typically with patellar-tendon-bearing or total-surface-bearing socket and a dynamic-response or microprocessor-controlled foot.
• Above-knee amputation (AKA) — reserved for failed BKA or higher-level disease; prosthetic ambulation is more energetically costly.

The contralateral foot after a major amputation is the foot at greatest risk. Weight-shifting onto a single insensate, neuropathic foot accelerates ulceration and Charcot in that foot. ~50% of unilateral diabetic amputees undergo contralateral amputation within 5 years (Izumi et al., Diabetes Care 2006). Prosthetic optimisation, contralateral footwear, and intensive surveillance of the surviving foot are essential.

Modern prosthetic options — microprocessor-controlled knees and ankles, osseointegrated implants, powered ankles — are improving function but are not universally available. For most patients, the decisive variable is not the technology of the prosthesis but the early and intensive rehabilitation programme that returns the patient to ambulation within 3–6 months of amputation.

8. Long-Term Outcomes & Mortality

Charcot is not just a foot disease; it is a marker of advanced systemic diabetes. The long-term outcome of CN patients reflects the combined cardiovascular, renal, and neurological burden:

Armstrong, Boulton and Bus (NEJM 2017; Diabetic foot ulcers and their recurrence) made the comparison that has reframed the field: the 5-year mortality after a major lower-extremity amputation in diabetes is ∼50–70%, substantially exceeding the 5-year mortality of breast cancer (~10%), prostate cancer (~5%), Hodgkin lymphoma (~12%), and even colorectal cancer (~35%). Diabetic foot disease is a malignant condition that is treated as a benign one.

The dominant causes of death are cardiovascular (~50–60%) — myocardial infarction, stroke, sudden death — followed by sepsis and renal failure. The advanced diabetic foot is in this sense a sentinel syndrome: the patient with Charcot is the patient at highest 5-year cardiovascular mortality. The clinical implication is to manage them as such: aggressive secondary cardiovascular prevention (statin, antiplatelet, ACE-inhibitor or ARB, blood-pressure control, smoking cessation, SGLT2-inhibitor or GLP-1 agonist as appropriate).

9. The Future of Charcot Care

Open questions and active investigation:

• Anti-RANKL therapy — the BoneCharcot RCT will inform whether denosumab improves clinical outcomes; if positive, will reframe pharmacotherapy of acute CN.
• Wearable thermography — smart-mat and in-shoe temperature monitoring to detect Stage 0 before clinical recognition; large prospective trials underway.
• Plantar pressure smart insoles — continuous in-shoe pressure measurement, real-time feedback to patient on overload events.
• Telemedicine foot exam — smartphone imaging + AI-based callus / ulcer detection in low-resource settings.
• Improved biomarkers — serum CTX, OPN, RANKL/OPG ratio, FGF-23 for CN activity tracking.
• Bone-health pharmacotherapy — teriparatide, romosozumab, sclerostin antibodies in Stage III consolidation; see Pharmacology.
• Surgical innovation — patient-specific 3D-printed plates, augmented-reality intra-operative navigation, biological augmentation (rhBMP, stem-cell-augmented arthrodesis).
• Continuous glucose monitoring — tighter glycaemic control with reduced hypoglycaemia, on the long causal pathway.
• Diabetic neuropathy disease-modifying therapy — the holy grail; nothing currently FDA-approved, but several molecules in late-stage trials.

The dominant message remains, as it has for two decades: recognise CN earlier; offload absolutely; involve the multidisciplinary team; manage the patient as a high-mortality chronic-disease patient, not as a foot complaint. Every consensus guideline since 2011 (IWGDF, ADA, AOFAS, NICE, Rogers) makes the same points; what changes is execution at the level of the primary-care encounter and the emergency department.

The Charcot foot is a window onto the broader diabetic-care system. Where the system works — integrated MDT, adequate primary-care screening, short referral pathways — CN patients keep their limbs and live longer. Where it does not, they do not. The clinical knowledge described in this course is necessary but not sufficient. The organisational and behavioural changes that turn knowledge into outcome are the work of the next decade.

We close as we began — in 1868, with Charcot, who saw in tabetic joint destruction the operation of the nervous system upon bone. He was right about the principle and, broadly, right about the mechanism. What he did not see was the diabetes pandemic that would re-write the demographics of the disease he named. The biology he described is now the terminal common pathway of millions of feet. Recognising it — early, clearly, and acting decisively — remains the central clinical task.